Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Share-based Compensation (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Share-based Compensation for 3 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 21.6% to $8.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.9 million, a 11.21% increase, with the full-year FY2025 number at $35.9 million, up 11.21% from a year prior.
  • Share-based Compensation was $8.0 million for Q4 2025 at Nuvation Bio, roughly flat from $8.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.0 million in Q2 2025 to a low of $3.7 million in Q4 2023.
  • A 3-year average of $7.3 million and a median of $7.7 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 173.75% in 2024, then decreased 21.6% in 2025.
  • Nuvation Bio's Share-based Compensation stood at $3.7 million in 2023, then soared by 173.75% to $10.2 million in 2024, then fell by 21.6% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Share-based Compensation are $8.0 million (Q4 2025), $8.0 million (Q3 2025), and $12.0 million (Q2 2025).